Vivus: Options Trade for FDA Panel Decision

| About: Vivus, Inc. (VVUS)

On July 15th the FDA Panel will be reviewing the weight loss drug made by Vivus (NASDAQ:VVUS).

If the panel gives a positive review of the drug then the stock can jump 50%, if they give the weight loss drug a negative review then the stock can drop 50%. Basically we are talking about VVUS being eiter $5 of $15 on July 16th.

The volatility of the options is 266%.

The option trade that I am considering is a covered call. (ie. buy the stock, sell the call option)

If I buy the stock at the time of writing this article, for $9.72, and I sell the $7 call for $4, that gives me a break even if the stock falls to $5.72. If the stock stays above $7 through option expiration, that means it would have to drop almost 30% and I stand to gain 20%.

Basically it is a risk of losing 10% and a potential reward of gaining 20% in two and a half weeks.

The reason I say it is a risk of losing 10% is because the options are looking for a move to $5 of $15. Usually the market makers are accurate and if it does drop, it will only drop to the amount of the at-the-money strangle.

I plan on buying a covered call position before July 15th, between $5.50 and $5.70.

Disclosure: No positions